
Gretta Stone Gretta Stone is a former deputy vice president of policy & research at PhRMA.
Recent Posts
New report details the setbacks and challenges to Alzheimer’s research

Illustrating the challenges of developing medicines to fight Alzheimer’s disease, a new analysis found that between 1998 and 2017, there were 146 unsuccessful medicines in clinical trials for...
Read More
ICYMI: Orphan drug development brings unique challenges

A new report from the Tufts Center for the Study of Drug Development finds that it takes 2.3 years, or 18 percent, longer to develop an orphan drug compared with medicines to treat more common...
Read More
New report portrays flourishing pipeline

It’s an exciting time to be working in the biopharmaceutical industry. Almost every day new headlines highlight remarkable new advances in the fight against disease. Some have called this the golden...
Read More
Using setbacks as stepping stones in Alzheimer’s research

For decades, biopharmaceutical researchers have worked tirelessly in the pursuit of new treatments and cures for the costly and devastating Alzheimer’s disease. Advancing treatments for Alzheimer’s...
Read More
New Study Illustrates Biopharmaceutical Industry’s Commitment to Personalized Medicine

Potential personalized medicines represent 42 percent of drugs in the pipeline. This new finding, from a survey by the Tufts Center for the Study for Drug Development (CSDD), is remarkably high,...
Read More